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Abstract  Article Info 
Introduction: Polymorphism of the enzyme in metabolyzing carcinogen such as CYP2E1 and GSTs are the 
genetic factor contributing for NPC. NPC also is related with several proteins that induce the growth and 
progression of tumor. Identification of the genetic variation and protein are beneficial for clinical use. 
Review: CYP2E1 polymorphisms are associated with increased activity and enzyme transcription, thereby 
increasing the activation of nitrosamines as carcinogens in NPC. In addition, polymorphism of GSTs as the 
phase II enzyme decrease the act to detoxify carcinogen and inhibit oxidative stress. Several studies showed the 
relation of those polymorphism with the risk factor of NPC. The protein expression in NPC was also studied by 
several researchers. Several proteins in NPC such as p38 MPAK, TNF-α, NF- κB, PPAR-gamma, LMP-1, 
VEGF, COX-2, and MMP-9 are related with tumor growth, prognosis and also help in treatment of NPC.  
Conclusion: Identifying GSTs and CYP2E1 polymorphism may be help in determining risk factor for NPC due 
to the association of those with increased susceptibility for NPC. Analyzing the protein expression by 
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Nasopharyngeal carcinoma (NPC) is a unique malignancy due to its 
clear geographic distribution [1, 2]. The incidence of NPC is high in South 
China, Southeast Asia, North Africa and Arctic and the disease is rare in 
another parts of the world [3]. In Indonesia, the incidence of NPC are 
8.3/100.000 for men and 3.0/100.000 for women [4]. NPC cases in 
Indonesia was about 12,000 cases per year [5]. The mortality of this 
malignancy is high because of the late diagnosis [6, 7]. The incidence of 
NPC in man is 2.3 fold higher than woman [8]. The average age of NPC 
patients is 50 years old [3].   
Nasopharyngeal carcinoma is caused by the relation of several factors 
including genetic, Epstein-barr Virus infection (EBV), and environment. 
Several genetic factors have role in NPC development such as Human 
Leukocyte Antigen-A2 (HLA-A2), chromosome 3p deletion and 
polymorphism of enzyme in carcinogen metabolism including cytochrome 
P450 2E1 (CYP2E1) (9). Study showed that there was expression of latent 
EBV such as Epstein Barr Virus Nuclear Antigen (EBNA), Latent 
Membrane Protein-1 (LMP-1), LMP-2, and EBV Encoded Small RNAs 
(EBER) in NPC. Almost 90% of NPC with poor differentiation are positive 
for EBV serology test [9]. Environmental factors which are responsible in 
NPC are geographic location, race or ethnic, and food such as salted fish 
and preserved food. Other factors including smoking, dust or combustion 
residue, chemical substances such as formaldehyde are also thought to be 
related with NPC [9, 10]. 
Recent years, the therapy for NPC are directed to targeted therapy 
which inhibit the specific cancer pathways and molecule that are involved 
in the growth and progression of cancer. The example is cetuximab which 
is the monoclonal antibody for Epidermal Growth Factor Receptor (EGFR), 
the growth factor that has role in tumor growth. Studies show that 
administration of cetuximab in the treatment of NPC using carboplatin is 
more effective in recurrent or metastatic NPC that fail with platinum therapy 
[11]. Another therapy is beacizumab, which is a monoclonal antibody that 
specifically binds to and inhibits VEGF, thereby inhibiting tumor 
angiogenesis. Combination of beacizumab with chemotherapy agents 
increases the apoptotic chemotherapy action. This suggests a possible 
combination of targeted therapy with chemotherapy in the management of 
NPC [12]. Several other molecular therapies are gene therapy, 
immunotherapy and adoptive therapy [11]. Apart from helping in therapy, 
the use of biomarkers can be used as a prognostic factor for NPC. Patients 
with negative VEGF and JAK2 expressions showed a longer survival time 
than patients with positive VEGF and JAK2 expressions [13]. The 
biomarkers are the expressed protein and can be analyzed by 
immunohistochemistry.  
2. MAIN TEXT 
2.1 Genetic Polymorphism in NPC 
Identification of gen in NPC provides an understanding of the 
molecular mechanisms of NPC. This is the basis for the discovery of 
biomarkers to assist in early diagnosis, therapy and prognosis of NPC [14, 
15]. CYP2E1 is one of the genes that plays a role in the activation of pro-
carcinogens such as nitrosamines found in cigarette smoke, salted fish and 
preserved food [14-16]. This enzyme polymorphism is associated with 
several cancers including NPC [16-18]. CYP2E1 polymorphisms are 
associated with increased activity and enzyme transcription, thereby 
increasing the activation of nitrosamines as carcinogens in NPC [9, 15, 16]. 
Study showed an increased risk of NPC associated with CYP2E1 
polymorphisms. This risk is further increased when accompanied by 
exposure to carcinogens containing nitrosamines such as tobacco from 
cigarette smoke [19-21]. The importance of CYP2E1 inhibitors has been 
investigated in liver cancer. Chlormethiazole which is a CYP2E1 inhibitor 
has been found to work in reducing hepatocyte proliferation and 
hepatocarcinogenesis induced by nitrosamine [22]. Research on NPC may 
be conducted to determine the benefit of this therapy in nasopharyngeal 
carcinoma. 
GSTs enzymes are enzymes that play a role in detoxifying carcinogens 
and inhibiting oxidative stress [23, 24]. Several types of GSTs enzymes 
include GSTA (α), GSTT1 (θ), GSTM1 (μ), GSTP1, GSTO1, GSTs and 
GSTZ1 (25). GSTM1 and GSTT1 are known to be associated with 
susceptibility to cancer. Deletions in genes, namely GSTM1 null and 
GSTT1 null cause loss of enzyme function in detoxifying carcinogens [26, 







27]. Several studies have shown that the risk of developing NPC was higher 
in individuals with GSTM1 null or GSTT1 null [28, 29].  Apart from 
GSTM1 and GSTT1, the GSTP1 polymorphism namely Ile / Val GSTP1 is 
also associated with several cancers such as breast cancer, lung cancer and 
head and neck cancer [30, 31]. This polymorphism changes the binding site 
of the GSTP1 substrate, causing changes in the function of GSTP1 in 
detoxifying carcinogens that can promote cancer development. However, 
several studies found that there was no correlation between GSTP1 
polymorphisms and NPC [28, 30].  GST enzyme polymorphisms also cause 
interference with the inhibition of oxidative stress caused by the 
accumulation of ROS [23]. Provision of antioxidants in cancer cases can be 
a consideration for NPC therapy based on the occurrence of oxidative stress. 
Studies show that there is an increase in superoxide dismutase, catalase, 
GST and glutathione reductase as an antioxidant enzyme and a decrease in 
DNA damage in a group of breast cancer patients with chemotherapy and 
intake of vitamin C and vitamin E supplements [32].  
2.2 Protein Expression in NPC 
Immunohistochemistry to detect protein expression has been performed 
in several studies to determine the diagnosis, prognosis and evaluation of 
cancer therapy, including NPC. The protein are: 
2.2.1 p38 Mitogen-Activated Protein Kinase (p38 MAPK) 
MAPK plays a role in cell growth including proliferation, 
differentiation and apoptosis of cells [33]. MAPK is associated with anti-
apoptotic activation that causes cell transformation (34). Studies showed 
that there was a significant relationship between p38 MAPK expression and 
clinical stage in NPC [35]. The use of MAPK as a therapeutic target has 
been identified as a strategy against cancer [36]. The work of MAPK as a 
transcription regulator that functions through the control of gene expression 
as a process that often experiences dysfunction in disease makes MAPK a 
target therapy option [37]. A study of preclinical activity of the anticancer 
drug gefitinib in non-keratinized NPC showed suppression of epidermal 
growth factor induced by p-EGFR, p-MAPK, and p-STAT3 activation [38]. 
A PCR study on the MAPK pathway and the Aur-A protein showed that 
MAPK overexpression led to overexpression of Aur-A protein, which 
subsequently led to intracranial invasion and increased staging of NPC. [39]. 
2.2.2 Tumor Necrosis Factor-α (TNF-α) 
TNF-α is known to be associated with malignancy and poor prognosis 
and cachexia. High levels of TNF-α are found in progressive NPC with an 
advanced rather than an early stage [40]. TNF-α can lead to increased tumor 
growth, stimulate the angiogenesis process, DNA damage and increase 
tumor metastasis potentiation in animal models [41]. TNF-α also increases 
tumor angiogenesis through several angiogenic factors such as interleukin-
8 (IL-8) and Vascular Endothelial Growth Factor (VEGF) [42]. TNF-α 
overexpression is closely related to tumor recurrence and tumor spread to 
the lymph nodes [43]. Andersson et al found that TNF-α has high levels in 
advanced stages of head and neck cancer and was a potential biomarker for 
prognosis along with C-Reactive Protein (CRP) [44]. Study showed the 
potential of TNF-α monoclonal antibody as a good therapy in preventing the 
growth of NPC [45]. 
2.2.3 Nuclear Factor-Kappa B (NF-κB) 
NF-κB in tumors play an active role in carcinogenesis through cell 
proliferation, cell apoptosis, inflammation and the immune system [46]. The 
roles of NF-κB in cell proliferation are activating cyclin D1 and c-myc 
expression, which are oncogens to induce cell proliferation. The targets of 
these transcription factors include TNF, Interleukin (IL) -8, and IL-1β which 
also work to stimulate cell proliferation [47]. NF-κB is also associated with 
cell invasion and tumor metastasis through induction of Epithelial-
Mesenchymal Transition (EMT) [47].   
NF-κB was found to be overexpressed in patients with NPC. The 
expression of these transcription factors is also associated with a poor 
prognosis for NPC [48]. The survival rate of patients with NF-κB expression 
was lower than without NF-κB expression [49]. Several targeted therapies 
for NF-κB include β-Hydroxyβ-methyl Butyrate (HMB), SPA3015 (P-
glycoprotein (P-gp) analogue which inhibits the proliferative effect of NF-
κB through inhibition of these transcription factors [50, 51]. 
2.2.4 Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-
gamma) 
PPAR-gamma has role in inflammation, glucose metabolism and cancer 
[52]. PPAR-gamma expression can inhibit cell proliferation and tumor 
growth, but can also stimulate proliferation in some cancer cells [52]. 
Studies show that PPAR-gamma can induce angiogenesis via VEGF 
stimulation in cancer cells [53]. PPAR-gamma expression is found in 
liposarcoma, breast cancer, colon cancer and prostate cancer [54]. 
 PPAR-gamma expression is known to be associated with higher tumor 
staging and lower survival rates in patients with pancreatic carcinoma [55]. 
Study showed a significant reduction in the incidence of head and neck 
cancer in diabetes mellitus patients treated with thiazolidinedione which is 
a PPAR agonist [56]. However, there were studies that show the possibility 
of PPAR agonists in the induction of cancer such as pioglitazone which is 
associated with an increased risk of bladder cancer depending on the dose 
and duration of therapy [57].  
2.2.5 Latent Membrane Protein-1 (LMP-1) 
LMP-1 is expressed in about 65% of NPC. This protein is important in 
the formation of tumors associated with EBV infection [9]. LMP-1 is a proto-
oncogen that is expressed by latent EBV infection [10, 58]. LMP-1 is known 
to activate several signaling pathways such as the signal pathways NF-κB, 
MAPK (Erk1 / 2, JNK. P38), STAT3, PI3-kinase/Akt, and others that play a 
role in the development of NPC (59, 60). LMP-1 are also involved in cell 
motility, cell invasion, cell proliferation and angiogenesis [61].  
Rosales et al. demonstrated that LMP-1 expression was associated with 
parapharyngeal cavity invasion. This expression is thought to be associated 
with a poorer prognosis in patients with NPC [62]. A study by Yang et al 
showed that there was inhibition of cell proliferation in the therapy of NPC 
using DNAzymes. This therapy is a synthetic single-chain DNA catalyst that 
works through LMP-1 genetic manipulation. This agent causes decreased 
LMP-1 expression in NPC [63]. 
2.2.6 Vascular Endothelial Growth Factor (VEGF) 
VEGF is known as a growth factor that plays a role in angiogenesis 
which is important in tumor growth, migration and endothelial proliferation 
[64]. VEGF is also known to be associated with tumor stage, lymph node 
involvement and metastases [65]. Study showed that NPC patients with 
VEGF overexpression have a poor prognosis compared to those without 
VEGF expression [66]. Dan et al. found that VEGF overexpression is an 
independent prognostic factor in NPC [67].   
2.2.7 Cyclooxygenase-2 (COX-2) 
COX-2 is involved in prostaglandin production, inflammation and cancer 
[68, 69]. COX-2 activity produces prostaglandin E2 (PGE2) products which 
cause carcinogenesis through cell protection against apoptosis, potentiation of 
cell proliferation, angiogenesis, invasive and metastatic [68, 69]. Study showed 
an association of COX-2 overexpression with low survival in patients with NPC 
(66). COX-2 overexpression is also associated with tumor size, lymph node 
involvement, clinical stage, distant metastases, tumor recurrence in patients with 
NPC [70, 71]. The majority of current studies focus on the prognostic value of 
COX-2 and the benefits of COX-2 inhibitors in cancer. COX-2 inhibitors in 
cancer therapy are generally associated with other factors such as Matrix 
Metalloproteinase (MMP) and TNF-α [72, 73]. 
2.2.8 Matriks Metalloproteinase-9 (MMP-9) 
MMP-9 is an enzyme that is often found in inflammation and neoplasia 
[73, 74]. This enzyme is involved in the growth of angiogenesis, migration 
and invasion of tumor cells. MMP-9 clears collagen types IV, V, XI, and 
XVI which are important in cell invasion and metastasis [74].  
High levels of MMP-9 expression are associated with a poor prognosis 
and advanced stage in several tumors including NPC [74-76]. Celecoxib, 
which is a COX-2 inhibitor, causes a decrease in MMP-9 expression in NPC 
cells in vitro. This is also in line with studies on pancreatic carcinoma cells 
[72, 73]. MMP-9 can be an important target in treating cancer [77]. 








CYP2E1 acts in the activation of pro-carcinogens such as nitrosamines 
and GSTs are involved in detoxifying carcinogens. The polymorphism of 
those enzyme increase the risk for NPC because of enhanced acitivity and 
diminished detoxification of carcinogen. Besides, protein expression in 
NPC tumor such as p38 MPAK, TNF-α, NF- κB, PPAR-gamma, LMP-1, 
VEGF, COX-2, and MMP-9 also affect the development and progression of 
cancer cells. Identification of risk factor and protein are help the clinician 
manage and prevent NPC. 
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